Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas.
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Alveolar soft part sarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Paraganglioma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Jun 2017 Status changed from active, no longer recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2016.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2016.